These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 20727170)

  • 1. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
    Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
    BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
    Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
    Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
    Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
    Ma Z; Wang X; He J; Xia J; Li Y
    PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
    Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
    Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
    BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
    Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Guo P; Xiong X; Zhang S; Peng D
    Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
    Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
    Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.